MRSN - Mersana Therapeutics Inc Stock Price, Fair Value and News

$27.88+0.36 (+1.31%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MRSN Price Action

Last 7 days

1.2%

Last 30 days

195.3%

Last 90 days

291.6%

Trailing 12 Months

-52.9%

MRSN RSI Chart

MRSN Valuation

Market Cap

139.4M

Price/Earnings (Trailing)

-1.99

Price/Sales (Trailing)

4.2

EV/EBITDA

-1.23

Price/Free Cashflow

-1.87

MRSN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MRSN Fundamentals

MRSN Revenue

Revenue (TTM)

33.2M

Rev. Growth (Yr)

-12.61%

Rev. Growth (Qtr)

260.24%

MRSN Earnings

Earnings (TTM)

-70.0M

Earnings Growth (Yr)

34.79%

Earnings Growth (Qtr)

69.13%

MRSN Profitability

EBT Margin

-207.28%

Return on Equity

117.61%

Return on Assets

-111.71%

Free Cashflow Yield

-53.36%

MRSN Investor Care

Shares Dilution (1Y)

1.16%

Diluted EPS (TTM)

-13.9

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	34.0M	34.8M	33.2M	0
2024	38.3M	29.9M	34.8M	40.5M
2023	32.3M	38.7M	40.8M	36.9M
2022	4.5M	8.2M	11.9M	26.6M
2020	0	28.4M	14.6M	828.0K
2019	48.6M	44.6M	43.3M	42.1M
2018	16.3M	16.8M	12.7M	10.6M
2017	25.8M	23.3M	26.3M	17.5M
2016	14.1M	17.8M	21.5M	25.2M
2015	0	0	0	10.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Mersana Therapeutics Inc

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has a research and development collaborations with Janssen Biotech, Inc. and Merck KGaA, as well as collaboration agreement with Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Martin H. Huber Jr., M.D.
WEBSITE	mersana.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	228

Mersana Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Mersana Therapeutics Inc? What does MRSN stand for in stocks?

MRSN is the stock ticker symbol of Mersana Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mersana Therapeutics Inc (MRSN)?

As of Wed Dec 03 2025, market cap of Mersana Therapeutics Inc is 139.37 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRSN stock?

You can check MRSN's fair value in chart for subscribers.

Is Mersana Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MRSN is over valued or under valued. Whether Mersana Therapeutics Inc is cheap or expensive depends on the assumptions which impact Mersana Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRSN.

What is Mersana Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, MRSN's PE ratio (Price to Earnings) is -1.99 and Price to Sales (PS) ratio is 4.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRSN PE ratio will change depending on the future growth rate expectations of investors.